Post

Larimar resumes nomlabofusp programme after FDA lifts partial hold

Larimar Therapeutics’ clinical programme investigating nomlabofusp (CTI-1601) for the treatment of a neurodegenerative movement disorder is back on track after …

Pheon cashes in on ADC trend and raises $120m in Series B

UK-based Pheon Therapeutics has raised $120m in a Series B round to fund the clinical trials for its oncology pipeline …

Explainer: US Election 2024 -Biden’s healthcare outlook

As a presidential election looms in the US, the incumbent democratic party has made strides to win over public, party …

Glenmark to market BeiGene’s oncology medicines in India

Glenmark Pharmaceuticals subsidiary Glenmark Specialty has entered an exclusive agreement to market and distribute two Beigene oncology medicines in India. Tislelizumab …

AmplifyBio and Xcell enter TCR T-cell therapy manufacturing deal

AmplifyBio and Xcell Biosciences have announced a strategic collaboration to advance the manufacturing process for engineered T-cell receptor (TCR) therapies. The …